Dr. Jedd Wolchok, M.D., Ph.D., FASCO, is Chief of the Immuno-Oncology Service and holds the Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK). He is also the Director at the Parker Institute for Cancer Immunotherapy at MSK and the Associate Director at the Ludwig Center for Cancer Immunotherapy. In 2018, he received the Fellow of the American Society of Clinical Oncology (FASCO) distinction. He received his M.D. from New York University School of Medicine and Ph.D. from New York University Graduate School of Arts & Sciences.

Dr. Wolchok has been at the forefront of novel cancer immunotherapies as an active clinician-scientist exploring innovative immunotherapeutic strategies in pre-clinical laboratory models and as a principal investigator in numerous pivotal clinical trials. He was instrumental in the clinical development leading to the commercial approval of ipilimumab for the treatment of advanced melanoma. His translational research lab at MSK focuses on innovative methods to modulate immune response to treat cancer and understand the mechanistic basis for sensitivity and resistance to current immunotherapies.

Dr. Wolchok’s work has been recognized with numerous awards, including the Alfred Taubman Prize for Excellence in Translational Medical Research, the American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award, the Virginia and Daniel K. Ludwig Chair for Clinical Investigation, the Melanoma International Foundation’s Doctor of the Year Award, the Melanoma Research Foundation Humanitarian Award, and the Damon Runyon-Lilly Clinical Investigator Award and most recently received the AACR-Joseph H. Burchenal Award.